bit.bio
bit.bio is a synthetic biology company focused on human cells that is advancing medicine and enabling curative treatments. The company does this by industrialising the manufacture of human cells and making them more accessible.
bit.bio’s opti-ox deterministic cell programming technology enables conversion of induced pluripotent stem cells (iPSCs) into any desired human cell type in a single step, at industrial scale, while maintaining exceptional purity and consistency. Our discovery platform extends this approach to any desired cell type by identifying the transcription factor combinations that define cell states (including identity, cell subtype identity, maturity) using high throughput screens and advanced data analysis.
The company has a cell therapy pipeline, based on tx Cells, focused on serious diseases that lack effective treatments. The lead candidate, bbHEP01 based on tx Hepatocytes, is in development as a treatment for patients suffering from acute liver failure and acute-on-chronic liver failure. The io Cells research cell product portfolio is opening up new possibilities for studying human biology and developing new medicines in research and drug discovery.
